NK CELLS FOR USE WITH ANITBODIES IN CANCER THERAPY
Natural Killer (NK) cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Modified NK cells and NK cell lines are produced via genetic modification of CD 38 low NK cells to transiently express the Fc receptor CD16 (F158V) from mRNA introduced into the NK cell, rather than from a chromosomal coding sequence. The cytotoxicity of the modified NK cells against CD38-expressing cancer cells is increased by administration of these modified cells in combination with a CD38-binding antibody. Separately, cytotoxicity against breast cancer is exhibited by the modified NK cells in combination with Herceptin.
1 . A natural killer (NK) cell transiently expressing an Fc receptor from an extra-chromosomal nucleic acid.
2 . The NK cell of claim 1 , wherein the extra-chromosomal nucleic acid is mRNA.
3 . The NK cell of claim 1 , wherein the Fc receptor is CD16.
4 . The NK cell of claim 3 , wherein the CD16 receptor comprises the amino acid substitution mutation F158V.
5 . The NK cell of claim 1 , wherein the NK cell is CD38 low .
6 . The NK cell of claim 1 , wherein the NK cell is of the KHYG-1 cell line.
7 . A method of treating cancer in a human patient, comprising administering to the patient an NK cell in combination with an antibody, wherein the NK cell transiently expresses an Fc receptor from an extra-chromosomal nucleic acid.
8 . The method of claim 7 , wherein the cancer is selected from the group consisting of acute myeloid leukemia, multiple myeloma and breast cancer.
9 . The method of claim 7 , wherein the antibody is selected from the group consisting of Daratumumab, Trastuzumab, Alemtuzumab, Brentuximab, Blinatumomab, Pankomab, Avelumab, Durvalumab and Atezolizumab.
10 . The method of claim 7 , wherein the extra-chromosomal nucleic acid is mRNA.
11 . The method of claim 7 , wherein the Fc receptor is CD16.
12 . The method of claim 11 , wherein the CD16 receptor comprises the amino acid substitution mutation F158V.
13 . The method of claim 7 , wherein the NK cell is CD38 low .
14 . The method of claim 7 , wherein the NK cell is of the KHYG-1 cell line.
15 . A pharmaceutical kit comprising (a) the NK cell of claim 1 ; (b) an antibody; and (c) instructions for administration of the NK cell and the antibody to a patient.
16 . The pharmaceutical kit of claim 15 , wherein the antibody binds CD38.
17 . The pharmaceutical kit of claim 15 , wherein the antibody binds HER2.
18 . The pharmaceutical kit of claim 15 , wherein the antibody is selected from the group consisting of Daratumumab, Trastuzumab, Alemtuzumab, Brentuximab, Blinatumomab, Pankomab, Avelumab, Durvalumab and Atezolizumab.
19 . A method of treating a CD38-expressing cancer in a human patient, comprising administering to the patient a CD38 low NK cell expressing an Fc receptor in combination with a CD38-binding antibody.
20 . The method of claim 19 , wherein the CD38-binding antibody is Daratumumab.